were assigned an identical index date as their matched case. Absenteeism costs in the 1 year post diagnosis were then estimated using a generalized linear model with log link and variance function determined by modified Park test (GLM). Shortterm disability costs were estimated with a two part model where the first part utilized a logistic model to determine the probability of having a short-term disability claim and the second part is a GLM model for patients who had such a claim. The analyses controlled for patient characteristics, prior medical costs, and general health. RESULTS: Patients with colorectal cancer in this study (Nϭ165) were mostly male (75.76%) with a mean age of 52 years. Patients with colorectal cancer were significantly less likely to be insured via point-of-service insurance (45.45% v 79.39%; pϽ0.0001) but more likely to be insured via a preferred provider organization (44.24% v 7.88%; PϽ0.0001) compared to their healthy matches (Nϭ165). After controlling for patient characteristics, prior medical costs and general health, patients with colorectal cancer experienced, on average, $6,075 higher short-term disability costs (PϽ0.0001) and $3,633 higher absenteeism costs (PϽ0.0001) in the 1 year post diagnosis of CRC. CONCLUSIONS: Results indicate that CRC is associated with significant work-related productivity loss costs in the first year post diagnosis.
OBJECTIVES: Due to advances in medical technology, cancer care costs are growing rapidly and expenditures with oncology treatment represents a significant burden for managed care organizations. Therefore, the study aims to evaluate the profile of oncology patients and treatment costs from UNIMED São José do Rio Preto (USJRP), a medical cooperative responsible for approximately 118,000 lives in São Paulo, Brazil. METHODS: A review of USJRP administrative claims database was conducted for patients who were under any cancer treatment between January 2011 to December 2011. Data regarding gender, age and treatment expenditures were assessed for the entire period. Only costs associated with treatment were taken into account (i.e. drugs, devices/materials and room taxes). Type of cancer was identified according to ICD-9 codes and grouped into major cancer types. Costs were reported in Brazilian Reais (1.00US$ϳ2.00BRL Jun/2012). RESULTS: A total of 324 oncology patients were identified (44.0% male and 56.0% female) with overall expenditures in the study period of BRL 4.57 million. Average age was 59.2 years (55.4 for female and 64.4 for male). Drugs accounted for 93.4% of all treatment expenditures, followed by room taxes with 4.2%. Average treatment cost per patient was BRL 14,105, being lymphoma the most expensive type of cancer (BRL 15, 544 per patient) . In terms of overall costs, breast cancer represented 43.8% of all treatment costs (BRL 1.98 million), followed by colorectal cancer (24.0%; BRL 1.10 million) and lung cancer (12.0%; BRL 0.55 million). CONCLUSIONS: More than 300 patients were treated for cancer in 2011 which accounted for approximately BRL 4.57million, being drugs responsible for more than 90% of all treatment expenditures. In 2011, health care costs reported for USJRP was BRL 217,849,541 (average of BRL 1,850 per life), demonstrating that costs associated with oncology treatment are high and suggesting the importance of economic evaluation of cancer drugs for the decision making process.
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IMPACT OF PHARMACY CHANNEL ON ABANDONMENT RATE OF ORAL ONCOLYTICS
United BioSource Corporation, Lexington, MA, USA OBJECTIVES: Oral chemotherapy agents are increasingly used for cancer treatment. The study objective was to quantify abandonment and reversal rates of oral oncolytics in patients filling prescriptions from traditional retail, Medco specialty, and other specialty pharmacies. Prescriptions are abandoned for different reasons including cost-sharing amounts and complexity of regimens prescribed. METHODS: Using a retrospective cohort design, we selected patients aged Ն18 years with a prescription for erlotinib, capecitabine, or imatinib during 2007-2011 from a Medco population of U.S. commercial and Medicare health plans. These agents represent widely available oral oncolytic agents. Patients were classified according to initial oncolytic received and pharmacy channel providing the medication. Abandonment was defined as a reversal following initial approval of prescription with no additional paid claims for the agent within 90 days of reversal. Overall reversal rates representing potential challenges filling prescriptions were also examined. Reversals occur for various reasons including incorrect information on claim or inability of patient to pay cost-sharing amount. RESULTS: Among patients treated with an oral oncolytic, 10,297 were prescribed erlotinib, 20,062 were prescribed capecitabine and 7,233 were prescribed imatinib. Mean age was 69.1, 61.3, and 62.1 years for erlotinib, capecitabine, and imatinib users, respectively. The abandonment rate of the initial oncolytic was 1.9%, 1.6%, and 1.2% for erlotinib, capecitabine, and imatinib, respectively. The rate of reversals was 4.9%, 3.7%, and 3.5% for erlotinib, capecitabine, and imatinib, respectively. For oncolytics examined, Medco specialty channel (0.2%) had lowest rates of abandonment versus other specialty (1.7% PϽ0.001) and retail (2.0% PϽ0.001). In multivariate models controlling for age, gender, and geographic region, specialty channel was significantly associated with filling the index prescription without challenges for all oncolytics. CONCLUSIONS: Low abandonment rates were observed in this study. The pharmacy channel in which patients fill their index oral oncolytic appears to be influential on patient abandonment rates. 
PCN106 PERSISTENCE IN PATIENTS WITH BREAST CANCER TREATED WITH TAMOXIFEN OR AROMATASE INHIBITORS: RESULTS OF A RETROSPECTIVE COHORT STUDY
Universityhospital of Giessen and Marburg GmbH, Marburg, Hessen, Germany
OBJECTIVES: High rates of compliance and persistence to medical treatments are associated with improved patient outcomes. Breast cancer survival has significantly increased, compliance with adjuvant treatment is very importance to ensure optimal treatment outcome. In this analysis, persistence i.e. the extent to which patients continue treatments was estimated for breast cancer patients on tamoxifen (TAM) and aromatase inhibitors (AI) treatment in primary care practices in Germany. METHODS: This retrospective cohort study analysed longitudinal routine care data collected by gynaecologists and general practitioners in Germany (IMS® Disease Analyzer). Non-persistence was defined as a period of Ն180 days without prescriptions. The lack of persistence was compared using Cox regression models after adjusting for age, gynecologist care, private health insurance, urban residency, practice in West-Germany, defined co-diagnoses and co-therapies (i.e. bisphosphonates). RESULTS: We included 12,412 patients diagnosed with primary breast cancer and first-time prescriptions of hormone therapy. A total of 7312 patients started with TAM (mean age 62.1 (SD: 13.5)), 5,100 with AI (anastrozole, exemestane, letrozole) (mean age 66.4 (SD: 10.6) as first line treatment. After 3 years 42.1% of TAM-patients and 40.2% of AI-patients in German practices discontinued their treatment. In the adjusted Cox model treatment in gynaecologist practice (HR: 0.46, pϽ0.001), age over 70 (HR 0.90, pϭ0.010), change of hormone therapy substance (HR: 0.82, pϽ0.001), co-therapy with bisphosphonates (HR: 0.86, pϭ0.013) and diagnosis of diabetes mellitus (HR: 0.82, pϽ0.001) were associated with a lower risk of discontinuation of therapy. No significant effect was found for western Germany, urban residency, private insurance status and other age groups. CONCLUSIONS: Long-term persistence on hormonal treatment in women with endocrine-responsive breast cancer is low. Factors affecting treatment discontinuation need to be identified and properly addressed. Patients at high risk of nonadherence to the prescribed medication should be cared for in more individualised fashion to ensure optimal treatment outcome.
PCN107 PERSISTENCE IN FIRST LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN ROUTINE CARE IN GERMANY
Mergenthaler U 1 , Morawski E 2 , Wendschlag A 1 1 IMS Health, Frankfurt, Germany, 2 Pfizer GmbH, Berlin, Germany OBJECTIVES: Metastatic renal cell carcinoma (mRCC) has a very high mortality rate with a 5 year survival of 5-15%. With the approval and use of a number of oral agents in the first line, treatment conditions for mRCC patients have significantly improved. Objective of this study was to evaluate the persistence in the first line treatment of mRCC patients in Germany. METHODS: The present study is based on the IMS LRx database containing 80% of all prescriptions reimbursed by the German statutory health insurance with an anonymized patient ID. The data base covers longitudinal information on patient level, such as age, gender, insurance company, region as well as prescriber specialty, date and medication on package level. Persistence was defined as the number of days from the date of the first prescription until the date of the last prescription plus the number of daily dosages prescribed. RESULTS: A total of 2799 patients starting first line treatment in mRCC between January 2010 and September 2010 were identified based on medication, co-medication and dosage. Median persistence in days was 84 for patients receiving Temsirolimus (T; nϭ384), 103 for Sorafenib (So; nϭ368), 117 for Pazopanib (P; A428 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 -A 5 7 5
